Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen
Nirav N. Shah(Medical College of Wisconsin), Narendranath Epperla(University of Utah), Lauren E. Strelec(University of Pennsylvania), Anikó Szabó(University of Wisconsin–Madison), Vaishalee P. Kenkre(University of Wisconsin–Madison), Horatiu Olteanu(Mayo Clinic in Arizona), Amanda F. Cashen(Washington University in St. Louis), Dheeraj Kodali(West Virginia University), Raya Saba(Saint Louis University Hospital), John L. Vaughn(Duke University), Abraham S. Kanate(HonorHealth), Timothy S. Fenske(Medical College of Wisconsin), Olukemi Esan(West Virginia University), David T. Yang(University of Wisconsin–Madison), Jakub Svoboda(UPMC Hillman Cancer Center), Anthony R. Mato(University of Pennsylvania), Mehdi Hamadani(Medical College of Wisconsin)
Cited by 16
Related Papers
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664